Indomethacin

Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) primarily used for its anti-inflammatory, analgesic, and antipyretic properties. While the provided studies and trials do not directly address the mechanism of action of indomethacin, general knowledge about NSAIDs can help elucidate its role:

Indomethacin works by inhibiting the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes are involved in the conversion of arachidonic acid to prostaglandins, which are compounds that contribute to inflammation, pain, and fever. By inhibiting COX enzymes, indomethacin reduces the production of prostaglandins, thereby alleviating inflammation and pain. This mechanism is consistent with its use in conditions such as arthritis and other inflammatory disorders.

Please note that while the references provided do not include details on the molecular action of indomethacin, this mechanism is widely recognized and established in the pharmacological literature.

Disclaimer: This content is for informational purposes only and not intended as medical advice. Always consult a healthcare professional for medical concerns.

Indomethacin is primarily used for its anti-inflammatory and analgesic properties. It is frequently utilized in the following clinical scenarios:

1. Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis Prevention: Indomethacin has been studied for its effectiveness in reducing the risk of pancreatitis following ERCP. The study titled "Confounding by Indication in Real-World Indomethacin Use for Post-ERCP Pancreatitis" highlights its potential role in mitigating the severity and associated costs of post-ERCP pancreatitis. Another systematic review compared rectal diclofenac and rectal indomethacin for this purpose, indicating their common use in clinical practice.

2. Acute Preterm Labor: A clinical trial (NCT02438371) focused on its role when combined with nifedipine for treating acute preterm labor, though this trial was terminated, indicating potential issues with efficacy or safety that are not detailed in the available data.

Despite these applications, it is important to note that the evidence is limited in terms of a broad range of well-documented clinical trials specific to indomethacin. The trials involving ketorolac and other compounds do not directly inform the clinical use of indomethacin. Given this, further research is likely needed to solidify its role and optimize its use in these and potentially other conditions.

Disclaimer: This summary is for informational purposes only and is not intended to provide medical advice. For medical concerns, please consult a healthcare professional.

Indomethacin Safety Profile

Known Side Effects:
Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) often used for pain and inflammation. Common side effects include gastrointestinal issues such as nausea, vomiting, dyspepsia, and the potential for gastric ulcers. It may also cause headaches, dizziness, and, less frequently, renal impairment.

Contraindications:
Patients with a history of hypersensitivity to indomethacin or other NSAIDs, those with active gastrointestinal bleeding or peptic ulcer disease, and individuals with severe renal impairment should avoid indomethacin. It is also contraindicated in individuals with perioperative pain in the setting of coronary artery bypass graft surgery.

Drug Interactions:
Indomethacin may interact with anticoagulants like warfarin, increasing the risk of bleeding. Concurrent use with other NSAIDs or high-dose aspirin can elevate the risk of gastrointestinal side effects. Indomethacin can also interact with antihypertensives, reducing their effectiveness, and with drugs like lithium, methotrexate, and diuretics, potentially increasing toxicity.

Populations to Avoid:
Pregnant women, particularly in the third trimester, should avoid indomethacin due to risks of fetal ductus arteriosus closure and oligohydramnios. Caution is advised in the elderly due to increased risk of adverse effects. Patients with a history of cardiovascular disease, renal impairment, or hypertension should use indomethacin with caution.

Evidence Thin Areas:
The provided studies and trials primarily focus on uses other than the general safety profile of indomethacin, such as its role in post-ERCP pancreatitis or dosage comparisons in unrelated drugs like ketorolac. Thus, specific recent data on indomethacin safety profile updates or novel side effects are limited in the given evidence.

Disclaimer:
The information provided here is intended for educational purposes and should not replace professional medical advice. Always consult a healthcare provider for personal medical concerns.

Key research papers and clinical trials on indomethacin focus on its use in various medical contexts, particularly for preventing post-ERCP pancreatitis. A systematic review found that both rectal diclofenac and rectal indomethacin are effective in preventing this condition, although the specific paper does not specify the sample sizes or detailed outcomes, indicating more research may be needed for conclusive evidence (Cureus, 2026).

Another study highlighted the complexities in real-world use of indomethacin for post-ERCP pancreatitis, pointing out the issue of "confounding by indication," which affects the cost and severity assessments. This suggests that patient selection and clinical settings can significantly influence study outcomes, underscoring the need for careful design in future research (Digestive diseases and sciences, 2026).

A clinical trial (NCT02438371) exploring the combination of nifedipine and indomethacin for acute preterm labor was terminated, indicating challenges potentially related to safety, efficacy, or other logistical reasons. Specific details about the trial's findings were not provided, reflecting a gap in data.

Other mentions of indomethacin in the research suggest interest in innovative detection methods, such as the development of chiral spirocycle coumarin-based nano fluorescence probes, although this study primarily relates to detection technology rather than clinical use (Spectrochimica acta, 2026).

This summary indicates a range of research interest in indomethacin, but additional focused studies are needed to clarify its clinical efficacy and applications across different settings.

Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult healthcare professionals for medical concerns.

Typical dosing and administration protocols for indomethacin, particularly in the context of preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, generally involve rectal administration.

Indomethacin Dosing Protocol

• Rectal Administration: The typical dose for preventing post-ERCP pancreatitis is a single dose of 100 mg administered rectally immediately before or after the procedure.

This is based on common practice and existing systematic reviews comparing the efficacy of rectal diclofenac and rectal indomethacin in this setting. However, specific dosing may vary depending on individual patient factors and clinical judgment.

Disclaimer

This information is intended for educational purposes and should not be considered personalized medical advice. Always consult with a healthcare provider for medical advice tailored to your situation.

The outcomes related to the use of indomethacin, particularly in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, are highlighted in recent literature. A systematic review compared the efficacy of rectal indomethacin with rectal diclofenac. The findings suggest that both medications are beneficial, but the systematic review does not provide explicit data on whether one is superior due to limited available comparative studies.

One study, "Confounding by Indication in Real-World Indomethacin Use for Post-ERCP Pancreatitis," implies potential implications on severity and cost, although specific outcome metrics are not detailed in the provided data.

Overall, the evidence suggests indomethacin may reduce the incidence of post-ERCP pancreatitis, but data directly measuring symptom improvement or specific biomarker changes is not thoroughly detailed in the available studies. The evidence base appears limited, and further research could help clarify these outcomes.

Disclaimer: This summary is for informational purposes only and should not be used for specific medical advice or treatment. Always consult a healthcare provider for medical advice.